胰十二指肠切除术围手术期抗生素预防的长期肿瘤学结局
本研究基于随机临床试验的注册链接数据,比较哌拉西林-他唑巴坦与头孢西丁在胰十二指肠切除术中的长期及肿瘤学结局。在匹配的426例患者中,两组辅助化疗遗漏率无显著差异,且哌拉西林-他唑巴坦与化疗实施无关联;但术后手术部位感染与较差的3年总生存相关。
要点
- 哌拉西林-他唑巴坦预防未显著影响肿瘤学治疗实施。
- 术后手术部位感染与较差的3年总生存相关。
- 围手术期并发症对肿瘤患者具有长期影响。
核心结论
- 发生手术部位感染的患者生存较差,但哌拉西林-他唑巴坦预防未显著影响肿瘤学治疗实施。
研究设计与样本
- 注册链接的随机临床试验,将美国外科医师学会国家手术质量改进计划数据库参与者记录与国家癌症数据库匹配。
主要发现
- 778例患者中471例(60.5%)在癌症委员会认证医院治疗并符合链接条件,其中426例(90.4%)匹配于国家癌症数据库,包括203例(47.7%)接受哌拉西林-他唑巴坦和223例(52.3%)接受头孢西丁。
- 在具有化疗指征的患者中,化疗遗漏率在治疗组间相似(哌拉西林-他唑巴坦组9.4% vs 头孢西丁组15.4%;P=0.097)。
- 接受指示辅助化疗与接受哌拉西林-他唑巴坦(OR 1.49;95% CI 0.56-3.95)或存在手术部位感染(OR 0.58;95% CI 0.21-1.65)无关。
- 术后手术部位感染与较差的3年总生存相关(HR 1.69,95% CI 1.20-2.38)。
临床怎么用
- 哌拉西林-他唑巴坦预防未显著影响肿瘤学治疗实施,但手术部位感染与较差生存相关,应重视围手术期并发症管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine long-term and oncologic outcomes of broad-spectrum perioperative antimicrobial prophylaxis, compared with standard care antibiotics, in patients undergoing pancreatoduodenectomy. BACKGROUND: A registry-linked randomized clinical trial demonstrated a reduction in surgical site infection (SSI) in patients undergoing pancreatoduodenectomy who received piperacillin-tazobactam as perioperative prophylaxis compared to cefoxitin. However, long-term outcomes remain undefined. METHODS: Participant records from the American College of Surgeons National Surgical Quality Improvement Program database were matched to the National Cancer Database. Associations between treatment arm, perioperative complications, and oncologic outcomes were assessed. Logistic regression models investigated associations with oncologic outcomes. Survival analyses used Kaplan Meier and Cox proportional hazard modeling. RESULTS: Of 778 patients, 471 (60.5%) were treated at Commission on Cancer accredited hospitals and eligible for linkage. Of those, 426 (90.4%) were matched in the NCDB including 203 (47.7%) treated with piperacillin-tazobactam and 223 (52.3%) with cefoxitin. Among patients with indications for chemotherapy, chemotherapy omission rates were similar between the treatment arms (9.4% in piperacillin-tazobactam vs 15.4% in cefoxitin; P=0.097). There was no association between the receipt of indicated adjuvant chemotherapy and receipt of piperacillin-tazobactam (OR 1.49; 95% CI 0.56-3.95) or presence of SSI (OR 0.58; 95% CI 0.21-1.65). Postoperative SSI was associated with poorer 3-year overall survival (HR 1.69, 95% CI 1.20-2.38). CONCLUSIONS: While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis.
引用
- Chan K, Palis BE, Thompson VM, et al. Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy. Ann Surg. 2026. PMID: 41731645. doi:10.1097/SLA.0000000000007031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。